The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I results from the phase 1/3 FIGHT study evaluating bemarituzumab and mFOLFOX6 in advanced gastric/GEJ cancer (GC).
 
Mohamedtaki Abdulaziz Tejani
Research Funding - Bayer (Inst)
 
Eric Cheung
No Relationships to Disclose
 
Peter D. Eisenberg
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); AVEO (Inst); Biomarin (Inst); Celgene (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Intercept Pharmaceuticals (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Millennium (Inst); PharmaMar (Inst); Plexxikon (Inst); Puma Biotechnology (Inst); Spectrum Pharmaceuticals (Inst); TG Therapeutics (Inst); Toray Industries (Inst)
 
Aaron James Scott
No Relationships to Disclose
 
Anteneh A. Tesfaye
Consulting or Advisory Role - Exelixis; Ipsen
 
Lyndah Dreiling
Employment - Five Prime Therapeutics; Gilead Sciences
Stock and Other Ownership Interests - Five Prime Therapeutics; Gilead Sciences
 
Clarence Eng
Employment - Five Prime Therapeutics
Stock and Other Ownership Interests - Five Prime Therapeutics
 
Neyssa Marina
Employment - Five Prime Therapeutics; Genentech/Roche (I)
Stock and Other Ownership Interests - Five Prime Therapeutics; Genentech/Roche (I)
Travel, Accommodations, Expenses - Five Prime Therapeutics
Other Relationship - Bristol-Myers Squibb; GlaxoSmithKline; Macrogenics; Novartis
 
Siddhartha Mitra
Employment - Five Prime Therapeutics
Stock and Other Ownership Interests - Five Prime Therapeutics; Gilead Sciences
Travel, Accommodations, Expenses - Gilead Sciences
 
Hong Xiang
Employment - Five Prime Therapeutics; Genentech/Roche
Stock and Other Ownership Interests - Amgen; Dynavax Technologies; Five Prime Therapeutics; Genentech/Roche; Gilead Sciences; Immunogen; Johnson & Johnson
 
Xiaohong Yan
Consulting or Advisory Role - Five Prime Therapeutics
 
Daniel V.T. Catenacci
Honoraria - Amgen; Bristol-Myers Squibb; Five Prime Therapeutics; Foundation Medicine; Genentech/Roche; Genmab; Gritstone Bio; Guardant Health; Lilly; Merck; NantWorks; OncoPlex Diagnostics; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; Astellas Pharma; Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck; Taiho Pharmaceutical
Speakers' Bureau - Foundation Medicine; Guardant Health